Why the study?
Does F(ab')2 FRaMon safely inhibit platelet aggregation compared to abciximab in patients undergoing high-risk coronary angioplasty?
Population
58 patients undergoing high-risk coronary angioplasty
Comparison
F2 FRaMon intravenous bolus at 0.2 mg/kg or 0.25… vs Abciximab 0.25 mg/kg bolus + 12 h infusion at…
Design
Cohort
Follow-up
1 month
Authors
Loading...
May support F(ab')2 FRaMon evaluation in angioplasty; leaves open efficacy versus abciximab in randomized trials.
Does F(ab')2 FRaMon safely inhibit platelet aggregation compared to abciximab in patients undergoing high-risk coronary angioplasty?
F(ab')2 FRaMon bolus administration provides comparable platelet aggregation inhibition and safety to abciximab bolus plus infusion in high-risk coronary angioplasty.
Мазуров et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: